drugset / Trial / NCT04989465
A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This an open phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunity persistence after single dose of 23-valent pneumococcal polysaccharide vaccine.
Timeline
- Start
- 2021-09-10
- Primary completion
- 2021-09-13
- Completion
- 2021-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | 25 ug | — |
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | — |